SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata
Guildford, UK, 10 June 2024 – SiSaf Ltd, a biopharmaceutical company that has developed a range of proprietary Bio-Courier® drug delivery technologies, today announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate (patchy) alopecia areata (AA), commonly known as spot baldness. This demonstrates the ability of SiSaf’s technology to deliver innovative new formulations that address stability, efficacy and side effect issues.
